Big news from one of our members: Turbine has closed a $25M Series B round, led by Interactive Venture Partners with participation from Beiersdorf Venture Capital.
Alongside the raise, the company is expanding beyond oncology with a new immunology collaboration with a Top 10 pharma partner, modeling immune biology and exploring combination therapies at computational scale.
Milestones like this highlight the growing global impact of Hungary’s life sciences and deep tech ecosystem.
👏 Congratulations to the Turbine team!
Big milestone!
We’ve closed a $25M Series B, led by Interactive Venture Partners with participation from Beiersdorf Venture Capital, a strong affirmation of confidence in our technology, our growing pharma traction, and the future of virtual biology.
We’re also moving beyond oncology, launching a new immunology collaboration with a (yet undisclosed) top 10 pharma company to model immune biology and rationally explore combination therapies at computational scale.
Biology is complex. Disease heterogeneity is massive.
We are virtualizating experiments to make it accessible.
Stay tuned: more pharma collaborations are in the making🔬
